Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAE TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Source: Senate LDA
| IRHYTHM TECHNOLOGIES INC |
| 8 |
| 2024–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | 2025–2026 |
| THE JED FOUNDATION | 8 | 2025–2026 |
| WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) | 8 | 2025–2026 |
| XEROX HOLDINGS CORPORATION (FORMERLY LEXMARK INTERNATIONAL, INC.) | 8 | 2025–2026 |
| BIOGEN, INC. | 7 | 2025–2026 |
| BIOHAVEN PHARMACEUTICALS, INC. | 7 | 2025–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2025–2026 |
| BOSTON DYNAMICS, INC. | 7 | 2025–2026 |
| NOVARTIS | 7 | 2025–2026 |
| UNITED WAY WORLDWIDE | 6 | 2025–2026 |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 6 | 2025–2026 |
| ASSOCIATION OF AMERICAN UNIVERSITIES | 5 | 2025–2026 |
| AVALYN PHARMA INC. | 5 | 2025–2026 |
| PONYA DIAGNOSTICS, LLC | 5 | 2025–2026 |
| REGENXBIO INC. | 5 | 2025–2026 |
| CALIFORNIA APARTMENT ASSOCIATION | 4 | 2025 |
| CORVENT MEDICAL, INC. | 4 | 2026 |
| MANHATTAN ASSOCIATES, INC. | 4 | 2026 |
| AIDOC, INC. | 3 | 2025–2026 |
| GALDERMA LABORATORIES, L.P. | 3 | 2026 |
| OPENAI OPCO, LLC | 3 | 2025 |
| PIVOTAL HEALTH | 2 | 2026 |
| RAINFALL HEALTH | 2 | 2026 |
| STAX ENGINEERING, INC. | 2 | 2026 |
| TAE TECHNOLOGIES, INC. | 2 | 2026 |
| TTX COMPANY | 2 | 2026 |
| MICHAELS STORES, INC. | 1 | 2026 |
| PARTICULA GROUP INC. | 1 | 2026 |
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
National Commission on Robotics Act
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
National Commission on Robotics Act
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334, National Commission on Robotics Act. H.R. 8189, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025.
National Commission on Robotics Act
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
American Security Robotics Act of 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
American Security Robotics Act of 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334, National Commission on Robotics Act. H.R. 8189, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025.
American Security Robotics Act of 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
National Defense Authorization Act for Fiscal Year 2027
Client: WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) · Firm: DLA PIPER LLP (US)
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
National Defense Authorization Act for Fiscal Year 2027
Client: WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) · Firm: DLA PIPER LLP (US)
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
National Defense Authorization Act for Fiscal Year 2027
Client: WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) · Firm: DLA PIPER LLP (US)
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
National Defense Authorization Act for Fiscal Year 2027
Client: CROWDSTRIKE, INC. · Firm: DLA PIPER LLP (US)
Policies and proposals related to cybersecurity. H.R. 8800, National Defense Authorization Act, FY 2027, policies and proposals related to cybersecurity.
National Defense Authorization Act for Fiscal Year 2027
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
National Defense Authorization Act for Fiscal Year 2027
Client: WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) · Firm: DLA PIPER LLP (US)
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
National Defense Authorization Act for Fiscal Year 2027
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Department of Homeland Security Appropriations Act, 2027
Client: MANHATTAN ASSOCIATES, INC. · Firm: DLA PIPER LLP (US)
H.R. 9310, Department of Homeland Security Appropriations Act for FY2027, provisions regarding funding for FEMA.
Department of Homeland Security Appropriations Act, 2027
Client: MANHATTAN ASSOCIATES, INC. · Firm: DLA PIPER LLP (US)
H.R. 9310, Department of Homeland Security Appropriations Act for FY2027, provisions regarding funding for FEMA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334, National Commission on Robotics Act. H.R. 8189, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
American Security Robotics Act of 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
American Security Robotics Act of 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision".
Client: STAX ENGINEERING, INC. · Firm: DLA PIPER LLP (US)
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision"
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision".
Client: STAX ENGINEERING, INC. · Firm: DLA PIPER LLP (US)
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision."
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax. Federal Student Aid.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BIOGEN, INC. · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, issues related to unmanned ground systems.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: BOSTON DYNAMICS, INC. · Firm: DLA PIPER LLP (US)
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, issues related to unmanned ground systems. Federal funding related to robotics via reconciliation. Engagement with Office of Science and Technology Policy, National Security Council and Department of Defense regarding a national robotics strategy.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Government strategy and advocacy on nuclear fusion technologies.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Medicare policies.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Independent dispute resolution under the No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Trade-related public policy around tariffs and intellectual property.
Issues related to tax reform.
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
RESEARCH SOCIETY ON ALCOHOL via DLA PIPER LLP (US)
2026 · third_quarter · Q3
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol related disorders.
Funding for alcohol related research and substance use disorders. Reform of National Institutes of Health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE JED FOUNDATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Policies related to social media, technology and impacts on mental health.
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Funding for the Department of Education mental health programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services. Matters affecting bundled payments and value based reimbursement. Proposals to extend coverage and payment for telehealth services. Medicare provider payment reform. Issues related to Medicare Advantage.
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Issues related to therapy services and telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
Insurance issues related to Medicare coverage; Medicare Advantage issues; issues related to CMS; telehealth issues.
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STAX ENGINEERING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TTX COMPANY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to truck size and weight issues. Surface Transportation Board reauthorization. Polices and proposals related to the railroad industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BOSTON DYNAMICS, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of
MANHATTAN ASSOCIATES, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
H.R. 9310, Department of Homeland Security Appropriations Act for FY2027, provisions regarding funding for FEMA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Tax reform and tax policy.
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to cybersecurity. H.R. 8800, National Defense Authorization Act, FY 2027, policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
CMS TEAM model, value-based care arrangements. CMS CJR-X model.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TTX COMPANY via DLA PIPER LLP (US)
2026 · third_quarter · RR
Policies and proposals related to truck size and weight issues; Surface Transportation Board reauthorization; polices and proposals related to the railroad industry.
STAX ENGINEERING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision"
TAE TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
Government strategy and advocacy on nuclear fusion technologies.
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · 2A
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
Independent dispute resolution under the No Surprises Act.
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
CMS TEAM model, value-based care arrangements.
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · second_quarter · RR
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare policies.
National security issues related to pharmaceutical industry, including supply chain.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
NOVARTIS via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Tariffs and biotechnology issues related to Treasury and competition with China.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Tax reform and tax policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
MICHAELS STORES, INC. via DLA PIPER LLP (US)
2026 · second_quarter · RR
Policies and proposals related to tariff and trade issues.
Policies and proposals related to tariff and trade issues.
BOSTON DYNAMICS, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 8800, National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334/S. 4686, National Commission on Robotics Act. H.R. 8189/S. 4235, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025. H.R. 9129, GUARD Act of 2026.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MANHATTAN ASSOCIATES, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
H.R. 9310, Department of Homeland Security Appropriations Act for FY2027, provisions regarding funding for FEMA.
RESEARCH SOCIETY ON ALCOHOL via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Funding for alcohol related research and substance use disorders. Reform of National Institutes of Health.
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol related disorders.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE JED FOUNDATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Policies related to social media, technology and impacts on mental health.
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Funding for the Department of Education mental health programs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
Issues related to military health TRICARE program. H.R. 8800, National Defense Authorization Act, FY2027, provisions regarding veterans health issues.
Insurance issues related to Medicare coverage; Medicare Advantage issues; issues related to CMS; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to university endowment tax.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTICULA GROUP INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to therapy services and telehealth.
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services. Matters affecting bundled payments and value based reimbursement. Proposals to extend coverage and payment for telehealth services. Medicare provider payment reform. Issues related to Medicare Advantage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BOSTON DYNAMICS, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. National Defense Authorization Act for FY2027, issues related to unmanned ground systems. H.R. 7334, National Commission on Robotics Act. H.R. 8189, American Security Robotics Act. S. 3275, Humanoid ROBOT Act of 2025.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Transportation, Dept of (DOT)
MANHATTAN ASSOCIATES, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Department of Homeland Security Appropriations Act for FY2027, provisions regarding funding for FEMA.
NOVARTIS via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Tariffs.
Tax reform and tax policy.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade policies and agreements, including IP protections, and administrative tariff actions.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to tax reform.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
AIDOC, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Government systems for AI integration. Regulation of AI medical technology.
Government systems for AI integration. Medicare coverage for AI technology.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2026 · first_quarter · 1T
Research security, research funding, and the importance of American research enterprise and higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Insurance issues related to Medicare coverage; Medicare Advantage issues; issues related to CMS; telehealth issues.
Issues related to military health TRICARE program; veterans health issues in the NDAA.
Issues related to military health TRICARE program; veterans health issues in the NDAA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH SOCIETY ON ALCOHOL via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Funding for alcohol related research and substance use disorders. Reform of National Institutes of Health.
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol related disorders.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE JED FOUNDATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Funding for the Department of Education mental health programs.
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Policies related to social media, technology and impacts on mental health.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to therapy services and telehealth.
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services. Matters affecting bundled payments and value based reimbursement. Proposals to extend coverage and payment for telehealth services. Medicare provider payment reform. Issues related to Medicare Advantage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR INC. via DLA PIPER LLP (US)
2026 · first_quarter · 1T
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Filing targets: SENATE
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · first_quarter · 1T
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.
Filing targets: SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · RR
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
MANHATTAN ASSOCIATES, INC. via DLA PIPER LLP (US)
2026 · first_quarter · RR
Homeland Security appropriations.
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Government systems for AI integration.
Government systems for AI integration.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Government systems for AI integration.
Government systems for AI integration.
INDIVIOR INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
NOVARTIS via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Tax reform and tax policy.
Tariffs.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Policies and proposals related to university endowment tax. Federal Student Aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BOSTON DYNAMICS, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Federal policy and legislation related to supporting the robotics industry and the intersection of robotics with artificial intelligence. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, issues related to unmanned ground systems.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH SOCIETY ON ALCOHOL via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol related disorders.
Funding for alcohol related research and substance use disorders. Reform of National Institutes of Health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE JED FOUNDATION via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Funding for the Department of Education mental health programs.
Encouraging activities that promote positive mental health/suicide prevention in K-12 schools and higher education, particularly comprehensive planning. Policies related to social media, technology and impacts on mental health.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
Issues regarding the Veterans Health Care Act of 1992.
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: Health & Human Services, Dept of (HHS), SENATE
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tax reform.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE